Tag Archive for: SITC

First-in-Human Study: Amplivant® Adjuvant Boosts Immune Response of Synthetic Long Peptide Immunotherapy

/in

First-in-human study investigating the safety and immunogenicity of ISA’s proprietary Amplivant adjuvant conjugated to human papillomavirus type 16 (HPV16) Synthetic Long Peptides (SLPs). SLPs conjugated to Amplivant elicit a significant, strong immune response and dose related systemic T cell immunity when injected intradermally. Study demonstrates that SLPs conjugated to Amplivant have highly favourable tolerability and […]

Read more

STORM Therapeutics to present new data on its lead program STC-15 at the 34th EORTC-NCI-AACR Symposium and the 37th SITC Meeting

/in

 STC-15 is an oral small molecule inhibitor of the RNA methyltransferase METTL3  STORM’s first-in-class lead program to enter clinical development in solid tumors in 2022  20 October 2022, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, is […]

Read more